araag2/HINT huggingface dataset:
Clinical trial NCT01820143 (phase 1, status: completed)
Conditions: healthy, pharmacokinetics, pharmacodynamics, ilaprazole
ICD codes: Z76.3, Z76.2
Drugs: ilaprazole, esomeprazole
SMILES: COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Prior to any study-specific procedures being performed, the subject voluntarily signed
             the approved informed consent/PIPEDA authorization form after having it fully
             explained and all questions answered.

          -  The subject was between 18 and 55 years, inclusive, and was generally in good health.

          -  Pregnancy test results for all females were negative in order to enter and remain in
             the study. A serum pregnancy test was performed on all females at Screening, Day -1 of
             each period, and Day 6 of Period 4 only, or if a subject prematurely discontinued.
             Results must have been negative in order for study drug to be administered.

          -  Female subject was using, and agreed to continue the use of, a double-barrier method
             of birth control. Oral, patch, implants, or injectable contraceptives were accepted as
             1 method if the subject had been taking them for greater than 2 months at the
             Screening Visit. Subjects who had a bilateral tubal ligation, hysterectomy, or
             bilateral oophorectomy for a minimum of 6 months, or surgical sterilization of partner
             (vasectomy for 6 months minimum), or were postmenopausal (defined as the absence of
             menses for 2 years or the absence of menses for 12 months and follicle-stimulating
             hormone [FSH] level of >40 IU/L) did not require the use of birth control.

          -  Subject had a negative breath test result for H pylori prior to enrollment.

          -  At the Screening Visit, subject had a body mass index (BMI) within the range of 18 to
             30 kg/m2, as determined by the following calculation.

          -  Subject was in general good health as evidenced by a medical history, a complete
             physical examination, and ECG without clinically significant abnormalities.

        Exclusion Criteria:

          -  Subject had current evidence of cardiovascular, central nervous system, hepatic,
             hematopoietic, renal, or metabolic dysfunction; serious allergy, asthma, history of
             significant sensitivity to any drug; or lactose intolerance that would contraindicate
             taking ilaprazole or esomeprazole or would interfere with the conduct of the study.
Clinical trial NCT00984438 (phase 1/phase 2, status: withdrawn)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: bcnu wafer, irinotecan, bevacizumab
SMILES: ClCCNC(=O)N(CCCl)N=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    no accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically proven diagnosis of GBM in the past with MRI findings compatible
             with disease recurrence. Multifocal disease is permitted.

          -  Must have had prior treatment with standard doses of Temodar

          -  KPS >50; ECOG <3

          -  Predicted life expectancy of > 3 months

          -  Study entry must be within 5 weeks of surgical resection

        Exclusion Criteria:

          -  Prior exposure to VEGF inhibitors or Irinotecan

          -  Intracranial bleed as defined by CT or MRI less than 6 months prior to entry

          -  GI bleed less than 6 months prior to entry

          -  Uncontrolled concurrent illness that would limit compliance with study requirements
Clinical trial NCT00379574 (phase 1/phase 2, status: completed)
Conditions: lymphoma, large-cell, diffuse, lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, cyclophosphamide, doxorubicin, vincristine, prednisolone, lenograstim
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed DLBCL

          -  Age 70 years or less

          -  Previously untreated

          -  Performance status: ECOG 0-2

          -  Advanced stage: stage III, IV, or non-contiguous stage II

          -  Measurable disease: 1 cm or more by spiral CT

          -  Normal liver function

        Exclusion Criteria:

          -  Platelet count less than 75,000/microL within 14 days before enrollment.

          -  Absolute neutrophil count of less than 1,500/microlL within 14 days before enrollment.

          -  Cr more than 2.0 mg/dL and/or calculated or measured creatinine clearance less than 50
             mL/min within 14 days before enrollment.

          -  Peripheral neuropathy of Grade 2 or worse within 14 days before enrollment.

          -  Hypersensitivity to bortezomib, boron or mannitol.

          -  Female subject is pregnant or breast-feeding.

          -  Other investigational drugs with 14 days before enrollment

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Uncontrolled or severe cardiovascular disease, including MI within 6 months of
             enrolment, New York Heart Association (NYHA) Class III or IV heart failure,
             uncontrolled angina, clinically significant pericardial disease, or cardiac
             amyloidosis
Clinical trial NCT02273388 (phase 1, status: active, not recruiting)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bi 6727
SMILES: [H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic
             solid tumours, who have failed conventional treatment, or for whom no therapy of
             proven efficacy exists, or who are not amenable to established forms of treatment

          2. Age 18 years or older

          3. Written informed consent consistent with ICH-GCP and local legislation

          4. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2

          5. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-,
             hormone-, immuno-, or radiotherapies (except alopecia)

             The 18 additional patients recruited at the MTD must also meet the following
             criterion:

          6. Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

        Exclusion criteria:

          1. Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          2. Pregnancy or breastfeeding

          3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection

          4. Clinical evidence of active brain or leptomeningeal disease during the past 12 months

          5. Second malignancy currently requiring active therapy

          6. Absolute neutrophil count less than 1500 / mm3

          7. Platelet count less than 100 000 / mm3

          8. Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)

          9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than 2.5 times the upper limit of normal (if related to liver metastases greater than
             five times the upper limit of normal)

         10. Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)

         11. Known history of relevant QT-prolongation, e.g. long QT-syndrome

         12. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         13. Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

         14. Chemo-, radio or immunotherapy within the past four weeks before start of therapy or
             concomitantly with this trial. This restriction does not apply to steroids and
             bisphosphonates.

         15. Patients unable to comply with the protocol

         16. Active alcohol or drug abuse
Clinical trial NCT00486265 (phase 1, status: terminated)
Conditions: acute myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: azd4877
SMILES: CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=C(C(C)=NS2)C(=O)N1CC1=CC=CC=C1
Reason stopped: 
    aml assess. of response in part b patients find treatment failure in all 8 evaluable for marrow
    response following a maximum of 2 induction courses of therapy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Part A: Relapsed or refractory leukemia for which no standard therapies are
             anticipated to result in a durable remission

          -  Part B: AML who have had no more than two prior relapses or failed to achieve
             remission after at least one induction treatment.

          -  Patients with prior allogeneic transplants who remain clinically stable for ≥2 weeks
             or more off immunosuppressive therapy

        Exclusion Criteria:

          -  Promyelocytic acute myelogenous leukemia

          -  Prior allogeneic transplant requiring immunosuppressive therapy or treating physician
             does not consider patient to be a candidate for allogeneic transplantation.

          -  Liver injury
Clinical trial NCT00867126 (early phase 1, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: pioglitazone hydrochloride
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Metastatic disease

               -  Previously treated disease

          -  Disease progression after first-line gemcitabine hydrochloride-based chemotherapy

          -  Radiologically measurable disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Serum creatinine < 1.5 times upper limit of normal (ULN) OR creatinine clearance > 45
             mL/min

          -  Total bilirubin ≤ 1.5 times ULN

          -  AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No NYHA class III-IV congestive heart failure

          -  No unstable angina

          -  No second malignancy except for localized nonmelanoma skin cancer

          -  No psychiatric or addictive disorders that would preclude giving informed consent

        PRIOR CONCURRENT THERAPY:

          -  Prior systemic therapy with fluorouracil, capecitabine, oxaliplatin, or erlotinib
             hydrochloride allowed

          -  More than 12 months since prior and no other concurrent thiazolinediones

          -  More than 6 months since prior treatment with immunosuppressive or immunomodulatory
             agents

          -  No other concurrent anticancer therapy
Clinical trial NCT01756404 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: canagliflozin (jnj-28431754), placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Volunteers must have a body mass index (BMI = weight in kg/height in m2) of 30.0 to
             39.9 kg/m2

          -  Volunteers must be non-diabetic as confirmed by fasting plasma glucose <126 mg/dL

          -  Volunteers must be non-smoker or non-tobacco users (not smoked cigarettes or used
             tobacco-containing products for 3 months prior to screening)

        Exclusion Criteria:

          -  History of or currently active illness considered to be clinically significant by the
             Investigator or any other illness that the Investigator considers should exclude the
             patient from the study or that could interfere with the interpretation of the study
             results

          -  History of having taken anti-obesity medications (prescription or non-prescription)
             within 3 months of the screening visit, or anticipates a need to take any of these
             drugs during the course of the study

          -  History of gastric banding, gastric bypass or other gastric-reduction surgery

          -  History of eating disorder or recent significant changes in body weight due to dieting
             or nutritional treatment
Clinical trial NCT01302145 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: asp1941, metformin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  Stable disease under metformin monotherapy (between 1500-3000

        mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative
        (SUD) for at least 3 months

          -  Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out)

          -  Stable Fasting Blood Glucose (FBG) at the end of wash-out

          -  BMI between 18.5 and 40.0 kg/m2, inclusive

        Exclusion Criteria:

          -  Subjects with type 1 diabetes

          -  Any diabetes related macro-complications, painful diabetic neuropathy, diabetic
             macular edema or diabetic proliferative retinopathy

          -  Clinical significant renal disease (CLcr <60 ml/min as assessed during a 24h
             creatinine clearance on Day-2

          -  Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example
             plasma glucose <3 mmol/l (<55 mg/dl) or requiring hospitalization

          -  Pulse <40 or >90; Systolic Blood Pressure >160 mmHg; Diastolic Blood Pressure > 100
             mmHg
Clinical trial NCT00356941 (phase 1, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    withdrawn due to lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:

               -  Medically inoperable or unresectable stage II, IIIA, or IIIB disease

               -  Post-resection intrathoracic tumor recurrence

          -  Measurable disease by computed tomography(CT) scan

          -  No evidence of small cell histology

          -  No significant pleural effusion on chest x-ray or malignant pleural effusion on
             cytology

          -  No metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1

          -  Absolute granulocyte count ≥ 2,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.0 g/dL

          -  Bilirubin ≤ 1.5 mg/dL

          -  Serum glutamic oxaloacetic transaminase (SGOT) ≤ 1.5 times upper limit of normal
             (unless abnormality is caused by documented benign disease)

          -  Creatinine ≤ 1.5 mg/dL

          -  Weight loss ≤ 10% within the past 3 months

          -  Forced expiratory volume (FEV) 1 ≥ 1,000 cc

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

        Exclusion Criteria:

          -  Synchronous (except for nonmelanomatous skin cancer) or prior invasive malignancy,
             unless disease free for > 3 years

          -  Myocardial infarction within the past 6 months

          -  Symptomatic heart disease, including any of the following:

               -  Angina

               -  Congestive heart failure

               -  Uncontrolled arrhythmia

          -  Active infection or fever ≥ 38.5°C within the past 3 days

          -  Known hypersensitivity to any of the components of oxaliplatin or docetaxel

          -  Prior thoracic or neck radiotherapy

          -  Prior docetaxel or oxaliplatin
Clinical trial NCT00491751 (phase 1, status: terminated)
Conditions: peripheral arterial disease
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: atorvastatin, ascorbic acid, placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female subjects age 21-99 years old.

          2. Peripheral Arterial Disease. PAD is defined clinically and by angiography, magnetic
             resonance imaging, vascular ultrasound, or ankle brachial index less than 0.9.

          3. Able to provide informed consent and complete the study procedure.

          4. Patients undergoing non-emergent vascular surgery (peripheral arterial bypass,
             abdominal aortic aneurysm repair, carotid endarterectomy, or limb amputation) or other
             non-cardiac surgery.

        Exclusion Criteria:

          1. Emergent or urgent surgery that must be performed sooner than one week after
             enrollment

          2. Unstable angina, myocardial infarction, stroke, coronary revascularization, or
             decompensated heart failure within 1 month of enrollment. Patients who require cardiac
             catheterization and surgical or percutaneous coronary revascularization prior to
             vascular surgery will be excluded.

          3. Clinically evident major illness of other organ systems, including cancer, end-stage
             renal disease, hepatic failure, or other conditions that make participation
             inappropriate.

          4. Women who are lactating, pregnant, or of childbearing potential and not using a
             reliable contraceptive method. Pregnancy will be excluded by a urine pregnancy test.

          5. Patients with liver function tests or serum creatine kinase >3 times the upper limit
             of normal.

          6. Patients who have received an investigational drug within 30 days of enrollment.

          7. Patients or subjects with a history of a psychological illness or condition such as to
             interfere with the subject's ability to understand the requirements of the study.

          8. Known occlusive atherosclerosis of the subclavian artery or upper extremity, because
             such disease will interfere with induction of reactive hyperemia during the brachial
             artery ultrasound studies.

          9. Patients will be excluded if they are taking vitamin C in a dose greater than 2 times
             the Recommended Daily Allowance (>120 mg/day) within 1 month of enrollment.
Clinical trial NCT01032122 (phase 1, status: terminated)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    the only reason is that recruitment was not sufficient to meet the planned patient numbers,
    because complete remissions are still infrequent.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified non-ocular melanoma stage IIIc/IV, no evidence of disease

        Exclusion Criteria:

          -  ECOG (Eastern Cooperative Oncology Group) performance status > 2

          -  Ocular melanoma

          -  Immunodeficiency syndromes or hypogammaglobulinaemia

          -  Active autoimmune diseases

          -  Treatment with immunosuppressive agents other than steroids

          -  Depressed bone marrow function (Leukopenia <3000, platelet count <100.000)

          -  Cardiac insufficiency NYHA (New York Heart Association) IV

          -  active Hepatitis B,C, or HIV infection

          -  Pregnancy or lactation

          -  Interstitial pulmonary disease

          -  Former treatment with anti-CD20 antibody
Clinical trial NCT00378105 (phase 1/phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, lenalidomide, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with multiple myeloma based on standard diagnostic criteria or by the new
             International Myeloma Foundation 2003 Diagnostic Criteria

          -  Must not have been previously treated with any prior systemic therapy for the
             treatment of multiple myeloma

          -  Negative serum or urine pregnancy test

          -  Age 18 years or older

          -  Karnofsky performance status of greater or equal to 60

        Exclusion Criteria:

          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14
             days before enrollment

          -  Renal insufficiency (serum creatinine >2.5 mg/dL)

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  ANC (absolute neutrophil count)< 1000 cells/mm3

          -  Hemoglobin < 8.0 g/dL

          -  AST (aspartate aminotransferase) or ALT (alanine aminotransferase) greater than or
             equal to 2 x ULN (upper limit of normal)

          -  Concomitant therapy medications that include corticosteroids

          -  Myocardial infarction within 6 months prior to enrollment according to NYHA (New York
             Heart Association) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities

          -  Clinically relevant active infection or serious co-morbid medical conditions

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
             situ cervical, breast or prostate cancer

          -  Pregnant or breast-feeding

          -  Serious medical or psychiatric illness likely to interfere with participation in study

          -  Uncontrolled diabetes mellitus

          -  Hypersensitivity to acyclovir or similar anti-viral drug

          -  POEMS syndrome

          -  Known HIV infection

          -  Known active hepatitis B or C viral infection

          -  Known intolerance to steroid therapy